Compare SINT & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SINT | IMRN |
|---|---|---|
| Founded | 1996 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 9.4M |
| IPO Year | 2007 | 2016 |
| Metric | SINT | IMRN |
|---|---|---|
| Price | $2.13 | $1.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $9.13 | N/A |
| AVG Volume (30 Days) | 29.4K | ★ 3.7M |
| Earning Date | 11-12-2026 | 08-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,018,000.00 | N/A |
| Revenue This Year | $190.28 | $16.39 |
| Revenue Next Year | $79.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.40 | $0.68 |
| 52 Week High | $4.64 | $2.38 |
| Indicator | SINT | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 66.00 | 44.88 |
| Support Level | $1.83 | $1.01 |
| Resistance Level | $2.46 | $1.22 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 64.20 | 10.53 |
SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.